幸运飞艇计划

CCBIO Special Seminar May 26th at 13.30-17.30.

Title: Pharma and public cancer biomarker research in the transition from a blockbuster model to personalised medicine

Organizer: Anne Blanchard, CCBIO postdoc.

Abstract:

Personalised cancer medicine gives rise to new opportunities and challenges. In this seminar we focus on the transition from a 鈥渂lockbuster鈥� drug model to the delivery of cancer therapies that are tailored to ever-smaller subgroups of patients that share some common biological and genetic characteristics.

Three main actors may face challenges in this transition: pharmaceutical companies may fear market fragmentation; public research encounters challenges of validating cancer biomarkers; and governmental agencies are confronted with the question of how to achieve a fair and sustainable allocation of cancer care.

Cooperation and collaboration between industry, public research and the government is clearly needed to meet the challenges. At the same time, the choice of collaborative model shapes the trajectory of drug development, cancer research and ultimately how society will understand cancer and organise its cancer care.

This special seminar brings together different perspectives on this transition. Researchers with broad experience from biomedicine, industry, government and social science meet to share their views and reflections on the challenges and opportunities this transition brings. We also hope for an active discussion with the audience!

Speakers and panellists:

Anne Blanchard, CCBIO

John Torgils Vaage, Oslo University Hospital

Jim Lorens, CCBIO/IBM, 幸运飞艇计划

Richard Godfrey, BerGenBio

Moderator: Roger Strand, CCBIO/SVT, 幸运飞艇计划

听

Indicative program:

13.30 - 13.35: Welcome by Roger Strand

13.35 - 14.00: Topical introduction by Anne Blanchard

14.00 - 14.30: General recommendations by John Torgils Vaage

14.30 - 15.00: Insights by Jim Lorens and Richard Godfrey

15.00 - 15.30: Panel discussion

15.30- 听 听 听 听 听听听PIZZA & informal interaction